Paul Tudor Jones Lyell Immunopharma, Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 124,320 shares of LYEL stock, worth $77,078. This represents 0.0% of its overall portfolio holdings.
Number of Shares
124,320
Previous 124,320
-0.0%
Holding current value
$77,078
Previous $180,000
5.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding LYEL
# of Institutions
121Shares Held
142MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$12.5 Million30.81% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$9.36 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$9.36 Million13.96% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$8.37 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$6.24 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $154M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...